NasdaqCM:GALT

Stock Analysis Report

Executive Summary

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Galectin Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.4%

GALT

3.1%

US Biotechs

1.8%

US Market


1 Year Return

-22.7%

GALT

-7.9%

US Biotechs

7.3%

US Market

Return vs Industry: GALT underperformed the US Biotechs industry which returned -7.9% over the past year.

Return vs Market: GALT underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

GALTIndustryMarket
7 Day-6.4%3.1%1.8%
30 Day-1.5%-2.4%-0.7%
90 Day-4.5%-0.8%0.06%
1 Year-22.7%-22.7%-7.1%-7.9%9.7%7.3%
3 Year371.6%371.6%14.2%10.3%46.3%36.9%
5 Year-25.0%-25.0%0.07%-4.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Galectin Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Galectin Therapeutics undervalued compared to its fair value and its price relative to the market?

4.38x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate GALT's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate GALT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GALT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: GALT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate GALT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GALT is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Galectin Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-8.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GALT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GALT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GALT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if GALT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if GALT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if GALT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Galectin Therapeutics performed over the past 5 years?

1.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: GALT is unprofitable, but has reduced losses over the past 5 years at a rate of 1% per year.

Accelerating Growth: Unable to compare GALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: GALT has a negative Return on Equity (-21.65%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: GALT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: GALT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Galectin Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: GALT's short term assets ($52.7M) exceeds its short term liabilities ($1.3M)

Long Term Liabilities: GALT's short term assets (52.7M) exceeds its long term liabilities (72.0K)


Debt to Equity History and Analysis

Debt Level: GALT is debt free.

Reducing Debt: GALT has not had any debt for past 5 years.


Balance Sheet

Inventory Level: GALT has a low level of unsold assets or inventory.

Debt Coverage by Assets: GALT's debt is covered by short term assets (assets are 3797074917828737559.460750x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GALT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GALT has sufficient cash runway for 2.408545 years if free cash flow continues to grow at historical rates of 19.8% each year.


Next Steps

Dividend

What is Galectin Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate GALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GALT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if GALT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GALT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GALT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Galectin Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.5yrs

Average board tenure


CEO

Harold Shlevin (69yo)

1.3yrs

Tenure

US$1,730,815

Compensation

Dr. Harold H. Shlevin, Ph.D., has been President and Chief Executive Officer at Galectin Therapeutics, Inc. since July 06, 2018. He was Chief Operating Officer and Corporate Secretary of Galectin Therapeut ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Harold's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Harold's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

3.5yrs

Average Tenure

72yo

Average Age

Experienced Board: GALT's board of directors are considered experienced (3.5 years average tenure).


Insider Trading

Insider Buying: GALT insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

SellUS$63,32515 Oct 19
10x Capital Management, LLC
EntityCompany
Shares17,000
Max PriceUS$3.73
SellUS$99,00009 Sep 19
Gilbert Amelio
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares30,000
Max PriceUS$3.30
BuyUS$4,78609 Sep 19
Kevin Freeman
EntityIndividual
Role
Vice Chairman
Independent Vice Chairman of the Board
Shares1,290
Max PriceUS$3.71
BuyUS$19,999,99503 Jun 19
Richard Uihlein
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares4,672,896
Max PriceUS$4.28
BuyUS$32,99903 Jun 19
Ed Uihlein Family Foundation, Endowment Arm
EntityCompany
Shares7,710
Max PriceUS$4.28
BuyUS$10,07503 Jun 19
Jack Callicutt
EntityIndividual
Role
Chief Financial Officer
CFO & Secretary
Shares2,354
Max PriceUS$4.28
BuyUS$12,98103 Jun 19
Kary Eldred
EntityIndividual
Shares3,033
Max PriceUS$4.28
BuyUS$39,10203 Jun 19
Kevin Freeman
EntityIndividual
Role
Vice Chairman
Independent Vice Chairman of the Board
Shares9,136
Max PriceUS$4.28
BuyUS$79,51403 Jun 19
Gilbert Omenn
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares18,578
Max PriceUS$4.28
BuyUS$54,99403 Jun 19
Joel Lewis
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares12,849
Max PriceUS$4.28
BuyUS$99,85109 Apr 19
Richard Uihlein
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares20,700
Max PriceUS$4.82
BuyUS$3,21408 Apr 19
Joel Lewis
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares667
Max PriceUS$4.82
BuyUS$100,97208 Apr 19
Richard Uihlein
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares21,000
Max PriceUS$4.81
BuyUS$2,36508 Apr 19
Kevin Freeman
EntityIndividual
Role
Vice Chairman
Independent Vice Chairman of the Board
Shares500
Max PriceUS$4.73
BuyUS$4,48411 Feb 19
Joel Lewis
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,000
Max PriceUS$4.48
BuyUS$6,42811 Feb 19
Kevin Freeman
EntityIndividual
Role
Vice Chairman
Independent Vice Chairman of the Board
Shares1,500
Max PriceUS$4.29
SellUS$150,00004 Feb 19
Gilbert Amelio
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares30,000
Max PriceUS$5.00
BuyUS$250,55931 Jan 19
Richard Uihlein
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares51,500
Max PriceUS$4.87
BuyUS$4,80530 Jan 19
Joel Lewis
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,000
Max PriceUS$4.81

Ownership Breakdown


Management Team

  • Jack Callicutt (52yo)

    CFO & Secretary

    • Tenure: 6.3yrs
    • Compensation: US$1.27m
  • Harold Shlevin (69yo)

    President & CEO

    • Tenure: 1.3yrs
    • Compensation: US$1.73m
  • Robert Tritt

    General Counsel

    • Tenure: 0yrs

Board Members

  • Gil Amelio (76yo)

    Independent Director

    • Tenure: 10.7yrs
    • Compensation: US$47.00k
  • Gilbert Omenn (77yo)

    Independent Director

    • Tenure: 5.1yrs
    • Compensation: US$45.00k
  • Jim Czirr (65yo)

    Director

    • Tenure: 10.7yrs
    • Compensation: US$38.50k
  • Stephen Shulman (75yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$41.44k
  • Dick Uihlein (74yo)

    Independent Chairman

    • Tenure: 1.4yrs
    • Compensation: US$35.00k
  • Marc Rubin (64yo)

    Independent Director

    • Tenure: 8yrs
    • Compensation: US$50.86k
  • Anatole Klyosov (72yo)

    Co-founder & Member of the Scientific Board

    • Tenure: 0yrs
    • Compensation: US$203.69k
  • Kevin Mayo

    Member of the Scientific Board

    • Tenure: 0yrs
  • Kevin Freeman (57yo)

    Independent Vice Chairman of the Board

    • Tenure: 1.8yrs
    • Compensation: US$46.00k
  • Joel Lewis (49yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$55.00k

Company Information

Galectin Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Galectin Therapeutics, Inc.
  • Ticker: GALT
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$216.914m
  • Shares outstanding: 56.78m
  • Website: https://galectintherapeutics.com

Number of Employees


Location

  • Galectin Therapeutics, Inc.
  • 4960 Peachtree Industrial Boulevard
  • Suite 240
  • Norcross
  • Georgia
  • 30071
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GALTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2002
PHPNDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2002

Biography

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company’s lead product candidate i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 23:49
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.